Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.
MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
MediPharm Labs Corp. (OTCQB: MEDIF) (TSX:LABS) (FSE:MLZ) has made its first delivery to the United States, and has completed the US FDA drug API manufacturer inspection at the company's Barrie, Ontario facility.
